CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia

Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by autoantibodies targeting platelet surface proteins, most commonly GPIIbIIIa (αIIbβ3 integrin), leading to platelet destruction. Recently, CD8+ cytotoxic T-lymphocytes (CTLs) targeting platelets and megakaryocytes have also been implicated in thrombocytopenia. Because steroids are the most commonly administered therapy for ITP worldwide, we established both active (immunized splenocyte engraftment) and passive (antibody injection) murine models of steroid treatment. Surprisingly, we found that, in both models, CD8+ T cells limited the severity of the thrombocytopenia and were required for an efficacious response to steroid therapy. Conversely, CD8+ T-cell depletion led to more severe thrombocytopenia, whereas CD8+ T-cell transfusion ameliorated thrombocytopenia. CD8+ T-regulatory cell (Treg) subsets were detected, and interestingly, dexamethasone (DEX) treatment selectively expanded CD8+ Tregs while decreasing CTLs. In vitro coculture studies revealed CD8+ Tregs suppressed CD4+ and CD19+ proliferation, platelet-associated immunoglobulin G generation, CTL cytotoxicity, platelet apoptosis, and clearance. Furthermore, we found increased production of anti-inflammatory interleukin-10 in coculture studies and in vivo after steroid treatment. Thus, we uncovered subsets of CD8+ Tregs and demonstrated their potent immunosuppressive and protective roles in experimentally induced thrombocytopenia. The data further elucidate mechanisms of steroid treatment and suggest therapeutic potential for CD8+ Tregs in immune thrombocytopenia. •CD8+ T cells play a predominantly protective role in both passive and active murine models of ITP.•CD8+ T-regulatory cells contribute to efficacious response to steroid therapy and may be important diagnostic/prognostic biomarkers for ITP.